MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$7,915K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of short-term investm...
Stock-based compensation expense
Proceeds from the exercise of st...
Others
Negative Cash Flow Breakdown
Global headcount expense
Purchases of short-term investme...
Commercial & medical affairs
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenue, net
60,112
189,757
-
-
Cost of sales
7,157
-
-
-
Cost of sales
7,157
19,492
-
-
Global headcount expense
58,653
172,648
-
-
Preclinical, clinical and development expense
18,511
87,322
-
-
Commercial & medical affairs
20,264
66,963
-
-
Corporate, general & administrative
7,888
35,348
-
-
Other segment expenses
-
0
-
-
Other (income) expense, net
-
-1,264
-
-
Other income (expense), net
-1,704
-
-
-
Interest income (expense), net
1,029
-5,290
-
-
Income taxes
545
497
-
-
Net loss
-55,639
-47,505
-52,904
-96,130
Stock-based compensation expense
23,099
19,266
18,810
28,742
Depreciation and amortization
252
272
304
762
Non-cash interest expense
4,577
4,616
4,742
11,226
Non-cash accretion & amortization of short-term investments
-1,436
-1,855
-1,695
-2,966
Non-cash rent expense
113
109
104
215
Change in fair value of embedded derivative liability
330
-130
-360
-420
Gain on settlement of forward contract
-
0
-
-
Acquired ipr&d assets classified as investing activities
-
0
-
-
Foreign currency (gain) loss
-1,791
-
-1,270
1,709
Other non-cash items
-178
-90
-
-
Accounts receivable
8,110
-6,175
6,600
7,145
Inventory
3,086
4,927
2,451
96
Prepaid expenses and other current assets
487
2,707
-6,385
10,005
Deferred revenue
-145
194
0
-1,286
Other long-term assets, net
-435
681
5,242
-5,526
Accounts payable, accrued expenses and other liabilities
-5,618
1,255
11,015
9,622
Net cash used in operating activities
-44,185
-25,389
-26,622
-63,664
Purchases of short-term investments
42,199
20,347
267,847
60,475
Maturities of short-term investments
99,251
51,647
61,500
139,322
Acquisition of ipr&d assets
-
0
40,000
-
Purchases of property and equipment
-
953
-
-
Net cash provided by investing activities
57,052
30,347
-246,347
78,847
Repayment of deferred royalty obligation
4,288
5,400
5,570
8,947
Proceeds from issuance of common stock-Public Offering
-
-
188,655
-
Proceeds from issuance of common stock upon completion of public offering, net of offering costs
-
188,657
-
-
Proceeds from the exercise of stock options
6,095
2,449
5,486
5,669
Tax withholding on vesting of restricted stock
8,458
-
-
-
Proceeds from issuance of common stock from espp
1,251
1
729
854
Proceeds from atm equity offering
0
1
-
34,034
Proceeds from royalty financing agreement, net of issuance costs
-
0
-
-
Gain on settlement of forward contract
-
0
-
-
Proceeds from issuance of common stock-At Market Offerings
-
-
34,035
-
Proceeds from series a preferred stock, net of issuance costs
-
0
-
-
Net cash provided by financing activities
-5,400
-2,948
189,301
31,610
Effect of exchange rates on cash
448
64
304
-281
Net increase (decrease) in cash, cash equivalents and restricted cash
7,915
2,074
-83,364
46,512
Cash, cash equivalents and restricted cash at beginning of period
54,823
52,749
89,601
-
Cash, cash equivalents and restricted cash at end of period
62,738
54,823
52,749
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of short-term
investments
$99,251K
Net cash provided by
investing activities
$57,052K
Effect of exchange
rates on cash
$448K
Canceled cashflow
$42,199K
Net increase
(decrease) in cash, cash...
$7,915K
Canceled cashflow
$49,585K
Purchases of short-term
investments
$42,199K
Stock-based compensation
expense
$23,099K
Non-cash interest
expense
$4,577K
Foreign currency (gain)
loss
-$1,791K
Other long-term
assets, net
-$435K
Change in fair value of
embedded derivative...
$330K
Depreciation and
amortization
$252K
Other non-cash items
-$178K
Non-cash rent expense
$113K
Proceeds from the
exercise of stock options
$6,095K
Proceeds from issuance of
common stock from espp
$1,251K
Net cash used in
operating activities
-$44,185K
Net cash provided by
financing activities
-$5,400K
Canceled cashflow
$30,775K
Canceled cashflow
$7,346K
Total revenue, net
$60,112K
Net loss
-$55,639K
Tax withholding on
vesting of restricted...
$8,458K
Canceled cashflow
$60,112K
Accounts receivable
$8,110K
Accounts payable,
accrued expenses and...
-$5,618K
Inventory
$3,086K
Non-cash accretion &
amortization of short-term...
-$1,436K
Prepaid expenses and
other current assets
$487K
Deferred revenue
-$145K
Repayment of deferred
royalty obligation
$4,288K
Global headcount
expense
$58,653K
Commercial & medical
affairs
$20,264K
Preclinical, clinical and
development expense
$18,511K
Corporate, general &
administrative
$7,888K
Cost of sales
$7,157K
Other income
(expense), net
-$1,704K
Interest income
(expense), net
$1,029K
Income taxes
$545K
Cost of sales
$7,157K
Buy us a coffee
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)